Barriers to monitoring and management of cardiovascular and metabolic health of patients prescribed antipsychotic drugs:
- PDF / 1,036,592 Bytes
- 15 Pages / 595.276 x 790.866 pts Page_size
- 61 Downloads / 191 Views
RESEARCH ARTICLE
Open Access
Barriers to monitoring and management of cardiovascular and metabolic health of patients prescribed antipsychotic drugs: a systematic review Ruba Azfr Ali1,2, Zahraa Jalal1 and Vibhu Paudyal1*
Abstract Background: The use of atypical antipsychotics which currently form the primary choice pharmacotherapy for several mental health conditions have been linked to cardiovascular and metabolic side effects. This systematic review aimed to investigate the barriers to monitoring and management of cardiovascular co-morbidities in patients prescribed antipsychotic medicines. Methods: A protocol-led (CRD-42018106002) systematic literature review was conducted by searching Medline, Embase, and PsycINFO databases 2003 until October 2019. Cochrane, Centre for Review and Dissemination (CRD) and PRISMA guidelines were followed. Studies investigating barriers to monitoring and management of cardiovascular co-morbidities in patients prescribed antipsychotic medicines were included. Results: A total of 23 records were included. Key barriers included a) health-care system-related factors such as lack of knowledge and expertise amongst care providers, available resources, confusion around remit and roles, fragmentation of care such as across general practitioners and psychiatrists, and time constraints and b) patientrelated factors such as disability resulting from mental health conditions, knowledge and skills of the patients. Conclusion: Barriers to monitoring and management of cardiovascular and metabolic health of patients taking antipsychotic medicines are multidimensional. Apart from educational interventions directed to both patients and health-care professionals, the results suggest a need for the improvement of wider system-related factors to improve physical health of patients prescribed antipsychotic medicines. Clearer guidelines, clarity of remit and roles amongst service providers are necessary in addition to educational interventions directed at patients and health-care professionals in improving physical health monitoring, counselling and management of patients prescribed antipsychotic medicines. Trial registration: A protocol was developed and registered with PROSPERO as per PRISMA-P guidelines (CRD 4201 8106002). Keywords: Antipsychotics, Comorbidity, Drug interactions and side effects, Patient Counselling research, Primary care
* Correspondence: [email protected] 1 School of Pharmacy, University of Birmingham, Birmingham, UK Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, un
Data Loading...
